[1]王海静,李　静,王永红,等.慢性阻塞性肺疾病患者外周血核苷酸结合寡聚化结构域样受体蛋白3水平与肺功能、病情程度和预后的关系[J].新乡医学院学报,2022,39(9):847-850.[doi:10.7683/xxyxyxb.2022.09.010]
　WANG Haijing,LI Jing,WANG Yonghong,et al.Relationship between peripheral blood NLRP3 level and lung function,disease severity and prognosis of patients with chronic obstructive pulmonary disease[J].Journal of Xinxiang Medical University,2022,39(9):847-850.[doi:10.7683/xxyxyxb.2022.09.010]
点击复制

慢性阻塞性肺疾病患者外周血核苷酸结合寡聚化结构域样受体蛋白3水平与肺功能、病情程度和预后的关系
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年9
页码:
847-850
栏目:
临床研究
出版日期:
2022-09-05

文章信息/Info

Title:
Relationship between peripheral blood NLRP3 level and lung function,disease severity and prognosis of patients with chronic obstructive pulmonary disease
作者:
王海静; 李　静; 王永红; 赵京梅; 李　颖; 肖　宁; 王芳芳
（邯郸市中心医院呼吸内科，河北　邯郸　056001）
Author(s):
WANG Haijing; LI Jing; WANG Yonghong; ZHAO Jingmei; LI Ying; XIAO Ning; WANG Fangfang
(Department of Respiratory Medicine,Handan Central Hospital,Handan 056001,Hebei Province,China)
关键词:
慢性阻塞性肺疾病; 核苷酸结合寡聚化结构域样受体蛋白3; 肺功能; 预后
Keywords:
chronic obstructive pulmonary disease; nucleotide binding oligomerization domain like receptor protein 3; lung function; prognosis
分类号:
R563
DOI:
10.7683/xxyxyxb.2022.09.010
文献标志码:
A
摘要:
目的　分析慢性阻塞性肺疾病（COPD）患者外周血核苷酸结合寡聚化结构域样受体蛋白3（NLRP3）水平与肺功能、病情程度和预后的关系。方法　选择邯郸市中心医院2018年1月至2019年6月收治的COPD患者102例为研究对象（观察组），另选择同期来院体检健康者40例作为对照组。根据预后情况将观察组患者又分为死亡组（n=37）和存活组（n=65）。观察组患者于入院第2天、对照组受试者于体检当日采用肺功能仪测定第一秒用力呼气容积（FEV1）占预计值（Pred）的百分比（FEV1%/Pred）、FEV1占用力肺活量（FVC）的百分比（FEV1/FVC）。观察组患者于入院第2天清晨、对照组受试者于体检当日抽取空腹外周静脉血约5 mL，采用酶联免疫吸附试验法测定血清中NLRP3水平。结果　观察组患者血清中NLRP3水平显著高于对照组，FEV1%/Pred和FEV1/FVC显著低于对照组（P<0.05）。随着COPD患者病情严重程度分级的增加，患者血清中NLRP3水平逐渐升高，FEV1%/Pred、FEV1/FVC逐渐降低，两两比较差异均有统计学意义（P<0.05）。Pearson相关性分析结果显示，患者血清中NLRP3水平与FEV1%/Pred和FEV1/FVC均呈负相关（r=－0.661、－0.618，P<0.05）。死亡组患者血清中NLRP3水平显著高于存活组（P<0.05）。结论　COPD患者血清中NLRP3水平高于健康人群，且随着病情的加重其水平呈上升趋势。NLRPS 水平与COPD患者肺功能呈负相关关系。
Abstract:
Objective　To analyze the relationship between the level of peripheral blood nucleotide binding oligomerization domain like receptor protein 3 (NLRP3) and lung function,disease severity and prognosis of patients with chronic obstructive pulmonary disease (COPD).Methods　A total of 102 COPD patients admitted to the Handan Central Hospital from January 2018 to June 2019 were selected as the study objects(observation group),and 40 healthy people who came to the hospital for physical examination during the same period were selected as the control group.The patients in the observation group were divided into death group (n=37) and survival group (n=65) according to the prognosis.On the second day of admission of patients in the observation group and on the day of physical examination of subjects in the control group,the ratio of forced expiratory volume in one second (FEV1) to predicted value (Pred) (FEV1%/Pred) and the ratio of FEV1 to forced vital capacity (FEV1/FVC) were measured by pulmonary function meter.On the morning of the second day of admission of patients in the observation group and on the day of physical examination of subjects in the control group,about 5 mL of fasting peripheral venous blood was taken and the serum NLRP3 level was determined by enzyme-linked immunosorbent assay.Results　The serum NLRP3 level of patients in the observation group was significantly higher than that in the control group,while the FEV1%/Pred and FEV1/FVC of patients in the observation group was significantly lower than that in the control group (P<0.05).With the increase of COPD grade,the serum NLRP3 level of patients gradually increased,and the FEV1%/Pred,FEV1/FVC gradually decreased;the difference among patients with different grade was statistically significant (P<0.05).Pearson correlation analysis showed that the level of serum NLRP3 of patients was negatively correlated with FEV1%/Pred and FEV1/FVC (r=－0.661,－0.618;P<0.05).The level of serum NLRP3 of patients in the death group was significantly higher than that in the survival group (P<0.05).Conclusion　The serum NLRP3 level of COPD patients is higher than that of healthy people,and the level of NLRP3 increases with the aggravation of the disease severity.The serum NLRP3 level is negatively correlated with lung function of COPD patients.

参考文献/References:

［1］　翁方中，胡朝梁，严骏，等.Relaxin-3通过抑制HMGB1介导的NLRP3炎性小体活化抑制AngⅡ诱导的心肌成纤维细胞转分化［J］.川北医学院学报,2021,36(8):953-958.
WENG F Z,HU C L,YAN J,et al.Relaxin-3 inhibits Ang Ⅱ-induced cardiac fibroblast transdifferentiation by inhibiting HMGB1-mediated activation of NLRP3 inflammasome［J］.J North Sichuan Med Coll,2021,36(8):953-958.
［2］　罗立，熊沿，聂晓红.慢性阻塞性肺疾病急性加重患者血NLR、CRP、EOS水平与病情严重程度的相关性［J］.川北医学院学报,2021,36(8):1006-1009.
LUO L,XIONG Y,NIE X H.Relationship between blood NLR,CRP,EOS levels and disease severity in patients with acute exacerbation of chronic obstructive pulmonary disease［J］.J North Sichuan Med Coll,2021,36(8):1006-1009.
［3］　侯梦瑶，邵明琨，罗丹丹，等.不同Sap酶活性的白假丝酵母菌对阴道上皮细胞表达NLRP3炎性小体的影响［J］.安徽医科大学学报,2021,56(10):1555-1560.
HOU M Y,SHAO M K,LUO D D,et al.Effect of Candida albicans with different Sap enzyme activities on NLRP3 inflammasomeexpression in vaginal epithelial cells［J］.J Anhui Med Univ,2021,56 (10):1555-1560.
［4］　JIN X,FU W,ZHOU J,et al.Oxymatrine attenuates oxidized low-density lipoprotein induced HUVEC injury by inhibiting NLRP3 inflammasome-mediated pyroptosis via the activation of the SIRT1/Nrf2 signaling pathway［J］.Int J Mol Med,2021,48(4):261-265.
［5］　梁海梅，欧宗兴，齐见旭，等.慢性阻塞性肺疾病急性加重期患者血清IL-34水平的变化及临床意义分析［J］.临床肺科杂志,2021,26(9):1431-1433.
LIANG H M,OU Z X,QI J X,et al.Changes and clinical significance of serum IL-34 levels in patients with acute exacerbation of chronic obstructive pulmonary disease［J］.Clin J Pulmon Med,2021,26 (9):1431-1433.
［6］　刘威，龙政，由金玲，等.2019年中国居民慢性阻塞性肺疾病死亡地点及影响因素分析［J］.中国慢性病预防与控制,2021,29(8):561-566.
LIU W,LONG Z,YOU J L,et al.Analysis of death places and influencing factors of chronic obstructive pulmonary disease among Chinese residents in 2019［J］.Chin J Prev Control Chron Dis,2021,29 (8):561-566.
［7］　CHUNSU Z,BO Z,JIAHAO Q,et al.Gout-associated monosodium urate crystal-induced necrosis is independent of NLRP3 activity but can be suppressed by combined inhibitors for multiple signaling pathways［J］.Acta Pharmacol Sin,2021,56(19):11515-11519.
［8］　QIN L,LIQIANG W,JING S,et al.Black carbon induces complement activation via NLRP3 inflammasome in human corneal epithelial cells［J］.Curr Eye Res,2021,59(46):16874-16878.
［9］　MANGAN M,OLHAVA E J,ROUSH W R,et al.Targeting the NLRP3 inflammasome in inflammatory diseases［J］.Nat Rev Drug Discov,2018,17(8):588-606.
［10］　ZHEN Y,ZHANG H.NLRP3 inflammasome and inflammatory bowel disease［J］.Front Immunol,2019,10(26):276.
［11］　LAREAU S C,FAHY B,MEEK P,et al.Chronic obstructive pulmonary disease (COPD)［J］.Am J Respir Crit Care Med,2019,199(1):1-2.
［12］　CASSADY S J,REED R M.Pulmonary hypertension in COPD:a case study and review of the literature［J］.Medicina (Kaunas),2019,55(8):4625-4629.
［13］　POLVERINO F,SAM A,GUERRA S.COPD:to be or not to be,that is the question［J］.Am J Med,2019,132(11):1271-1278.
［14］　陈凌,茅松,朱若尘,等.NLRP3抑制剂MCC950对中性粒细胞性哮喘气道炎症的影响及其作用机制［J］.中国生物制品学杂志,2022,35(7):829-835.
CHEN L,MAO S,ZHU R C,et al.Effect of NLRP3 inhibitor MCC950 on airway inflammation in neutrophilic asthma and its mechanism［J］.Chin J Biol,2022,35(7):829-835.
［15］　AGUST A,VOGELMEIER C,FANER R.COPD 2020:changes and challenges［J］.Am J Physiol Lung Cell Mol Physiol,2020,319(5):879-883.
［16］　KELLEY N,JELTEMA D,DUAN Y,et al.The NLRP3 inflammasome:an overview of mechanisms of activation and regulation［J］.Int J Mol Sci,2019,20(13):6151-6158.
［17］　ZHAO C,ZHAO W.NLRP3 inflammasome:a key player in antiviral responses［J］.Front Immunol,2020,11(62):211.
［18］　HOOFTMAN A,ANGIARI S,HESTER S,et al.The immunomodulatory metabolite itaconate modifies NLRP3 and inhibits inflammasome activation［J］.Cell Metab,2020,32(3):468-478.
［19］　SEOANE P I,LEE B,HOYLE C,et al.The NLRP3-inflammasome as a sensor of organelle dysfunction［J］.J Cell Biol,2020,219(12):5618-5622.
［20］　杨美琪,刘维新,来爽,等.核苷酸结合寡聚化结构域样受体蛋白1、3、6与炎症性肠病的关系［J］.中国医科大学学报,2019,48(5):457-460.
YANG M Q,LIU W X,LAI S,et al.Relationship between nucleotide-binding oligomerization domain-like receptor proteins 1,3,and 6 and inflammatory bowel disease［J］.J China Med Univ,2019,48(5):457-460.
［21］　刘萍,娄可,文隆,等.氧化应激介导NLRP3炎性反应小体对慢性阻塞性肺疾病的影响研究［J］.首都医科大学学报,2020，41(1):131-136.
LIU P,LOU K,WEN L,et al.Oxidative stress mediates the effect of NLRP3 inflammasome on chronic obstructive pulmonary disease［J］.J Capital Med Univ,2020,41(1):131-136.
［22］　赵开顺,楚亚萍,余艳芳,等.慢性阻塞性肺疾病急性发作患者血清CG、NT-proBNP、HIF-1α和NLRP 3蛋白表达的意义［J］.四川医学,2019,40(1):79-82.
ZHAO K S,CHU Y P,YU Y F,et al.The significance of serum CG,NT-proBNP,HIF-1α and NLRP3 protein expression in patients with acute exacerbation of chronic obstructive pulmonary disease［J］.Sichuan Med J,2019,40(1):79-82.

相似文献/References:

[1]史册.慢性阻塞性肺疾病急性发作期的营养支持治疗[J].新乡医学院学报,2001,18(06):444.
[2]袁晓梅,孙 云,袁宇.慢性阻塞性肺疾病肺心病患者血浆内皮素测定的临床价值[J].新乡医学院学报,2002,19(04):273.
[3]郭志强.慢性阻塞性肺疾病60例院内获得性真菌感染与耐药性分析 [J].新乡医学院学报,2006,23(02):000.
[4]程思远.慢性阻塞性肺疾病继发真菌感染65例病原菌分布及耐药性分析[J].新乡医学院学报,2009,26(01):073.
[5]杨华,周志才,奚峰,等.无创正压通气治疗慢性阻塞性肺疾病急性加重期伴Ⅱ型呼吸衰竭[J].新乡医学院学报,2011,28(02):216.
[6]殷波,惠复新,赵寅滢,等.慢性阻塞性肺疾病急性加重期三重酸碱失衡与急性生理学和慢性健康状况评分Ⅲ评分及预后的关系 [J].新乡医学院学报,2011,28(03):346.
[7]刘金花,徐吟亚,付波.低分子肝素钙对慢性阻塞性肺疾病急性加重期患者血栓前状态的影响[J].新乡医学院学报,2012,29(09):680.
[8]王 沁,郭建辉,梁 栋,等.健脾益肺口服液对慢性阻塞性肺疾病“肺脾气虚证”大鼠动脉血气的影响[J].新乡医学院学报,2014,31(11):896.[doi:10.7683/xxyxyxb.2014.11.00]
[9]朱木林１,袁云华１,邓　巍２,等.慢性阻塞性肺疾病合并外周骨骼肌功能障碍患者炎性因子和代谢水平及线粒体功能的变化[J].新乡医学院学报,2015,32(05):412.
[10]李　航,郭伟丽,安　珍,等.PM2.5对慢性阻塞性肺疾病影响研究进展[J].新乡医学院学报,2016,33(3):234.[doi:10.7683/xxyxyxb.2016.03.020]
　LI Hang,GUO Weili,AN Zhen,et al.Research progress on the effect of PM2.5 on chronic obstructive pulmonary disease[J].Journal of Xinxiang Medical University,2016,33(9):234.[doi:10.7683/xxyxyxb.2016.03.020]

更新日期/Last Update: 2022-09-05